AbbVie Files Patent Infringement Lawsuit Over Aurobindo’s Generic Rinvoq in Delaware Federal Court

On April 4, 2025, AbbVie initiated a patent infringement lawsuit in the federal court of Delaware, asserting that Aurobindo Pharma’s tentatively approved generic formulation of Rinvoq infringes on its intellectual property. This legal action represents the latest development in a series of patent-related disputes concerning Rinvoq, a prominent immunosuppressant medication used in the treatment of autoimmune conditions. The case underscores ongoing challenges in the pharmaceutical industry where patent rights and generic drug approvals frequently clash. Further details on this litigation can be found in the original article on Law360.